Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Cancer Antigen Specific Immunotherapy in Melanoma
NCT00004022Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jun 1997
- Primary completion
- Jan 2004
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of therapeutic autologous lymphocytes in melanoma, sponsored by Barbara Ann Karmanos Cancer Institute. Started Jun 1997; status: completed.
02
Drugs
therapeutic autologous lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00004022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004022.